Last reviewed · How we verify

NCT04954378

Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer

Completed Last updated 8 July 2021
What this trial tests

trial testing radiomics in Pancreatic Ductal Adenocarcinoma in 300 participants. Completed in 30 December 2020.

Timeline
1 January 2010
Primary endpoint
30 December 2020
30 December 2020

Quick facts

Lead sponsorPeking University Third Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment300
Start date1 January 2010
Primary completion30 December 2020
Estimated completion30 December 2020

Drugs / interventions tested

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Eligibility, any sex, with Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retrospectively analyzed radiomics features of pancreatic ductal adenocarcinoma to predict staging and prognosis

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of radiomics

Trials testing the same drug.

Other recruiting trials for Pancreatic Ductal Adenocarcinoma

Currently open trials in the same condition.

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04954378.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing